{"id":"NCT02468830","sponsor":"CHU de Quebec-Universite Laval","briefTitle":"Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder","officialTitle":"Prospective Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04","primaryCompletion":"2016-01","completion":"2016-03","firstPosted":"2015-06-11","resultsPosted":"2018-06-20","lastUpdate":"2018-06-20"},"enrollment":58,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Overactive Bladder","Urinary Incontinence"],"interventions":[{"type":"DRUG","name":"mirabegron","otherNames":["Myrbetriq"]}],"arms":[{"label":"Mirabegron","type":"EXPERIMENTAL"}],"summary":"The objective is to evaluate the efficacy and safety of mirabegron to treat urinary incontinence in children with Overactive Bladder that are refractory and/or intolerant to antimuscarinics.","primaryOutcome":{"measure":"Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron","timeFrame":"Participants will be followed for the duration of the study, up to 52 weeks","effectByArm":[{"arm":"Mirabegron","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":15},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26876327"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":58},"commonTop":["Transient abdominal colic","Constipation","Blurred vision","Nausea","Change in behavior"]}}